Annals of the Rheumatic Diseases最新文献

{"title":"Blinatumomab in dermatomyositis and refractory ANCA-associated vasculitis: a 2-patient exploratory study.","authors":"Ci Lu, Xuexiao Jin, Jialin Dai, Ning Shen, Shuangyue Ma, Xiayan Xu, Xin Li, Lihua Chen, Guannan Jiang, Qiao Ye, Qing Zhou, Linrong Lu, Yongmei Han","doi":"10.1016/j.ard.2026.10.3160","DOIUrl":"https://doi.org/10.1016/j.ard.2026.10.3160","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to explore the safety and efficacy of blinatumomab for the treatment of autoimmune diseases.</p><p><strong>Methods: </strong>Two patients, 1 with dermatomyositis (DM) and 1 with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), were treated with blinatumomab (CD19 × CD3 bispecific T-cell engager antibody) administered by continuous intravenous infusion for 2 cycles. Evaluations were conducted every 2 weeks until week 12, and then once every 4 weeks during continued follow-up through week 24, as well as on week 56. Immune cell dynamics were assessed by flow cytometry and single-cell RNA sequencing.</p><p><strong>Results: </strong>During the 14-month follow-up, we observed rapid T-cell activation and B-cell depletion in peripheral blood, together with clinical improvement in both patients, without cytokine release syndrome or other serious adverse events. Moreover, 12 weeks after treatment, both T cells and B cells returned towards a state of homeostasis, accompanied by reduced B-cell activation and downregulation of proinflammatory genes in myeloid compartments. Low-dose blinatumomab treatment was followed by sustained clinical improvement over the 14-month follow-up period, together with marked peripheral B-cell depletion and an acceptable safety and tolerability profile.</p><p><strong>Conclusions: </strong>This study provides longitudinal clinical and immunological observations of blinatumomab treatment in anti-Mi-2-positive DM and refractory AAV. These exploratory findings support further evaluation of blinatumomab in autoimmune diseases.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Making sense of publicly available omics dataset.","authors":"Caroline Ospelt","doi":"10.1016/j.ard.2026.10.3162","DOIUrl":"https://doi.org/10.1016/j.ard.2026.10.3162","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden and economic cost of musculoskeletal disorders in the working-age population, 1990-2023.","authors":"Zhanqi Wei, Xiang Ji, Ditao Lin, Zhou Chen, Zilong Wang, Hanyang Sun, Jie Tan, Chenliang Wang, Zehui Lv, Bin Feng, Fangang Meng, Xisheng Weng, Puyi Sheng","doi":"10.1016/j.ard.2026.10.3170","DOIUrl":"https://doi.org/10.1016/j.ard.2026.10.3170","url":null,"abstract":"<p><strong>Objectives: </strong>Musculoskeletal (MSK) disorders are the leading cause of years lived with disability (YLDs), yet their combined burden in the working-age population, where they impose the greatest productivity loss, has never been characterised as a whole. We quantified the global working-age (15-64 years) MSK burden and its economic cost, 1990-2023.</p><p><strong>Methods: </strong>In a secondary analysis of Global Burden of Disease Study 2023, we extracted disability-adjusted life-years (DALYs), YLDs, prevalence and incidence for the aggregate MSK cause at ages 15 to 64 years across 204 countries and both sexes, and assessed trends, Socio-demographic Index (SDI) association, inequality, decomposition, risk-attributable fractions, projections to 2050, and a cross-national model of direct and indirect costs.</p><p><strong>Results: </strong>In 2023, working-age MSK disorders caused 119.4 million DALYs (95% uncertainty interval [UI] 82.1-167.2; +77.2% vs 1990) and 1.22 billion prevalent cases; 98.6% of these DALYs were nonfatal. The burden was higher in women, rose with age, and was highest in high-SDI countries (r = 0.59), yet differed only modestly across SDI quintiles. Cost reached 5.27 trillion international dollars (95% UI 3.70-7.27), 89.0% indirect, with high-SDI countries bearing 77.6%. High body mass index attributable fractions rose, and the global DALY count is projected to rise 23.6% by 2050 (19.7%-26.2% across 5 models), whereas the age-standardised rate changes by <6% in every SDI stratum.</p><p><strong>Conclusions: </strong>The working-age MSK burden is large, rising, dominated economically by productivity loss and concentrated in developed and rapidly industrialising economies. Weight management and occupational ergonomics are priority targets for protecting workforce health.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of HFE genotypes and iron loading on joint disease: evidence for HFE-associated arthropathy without genetic haemochromatosis.","authors":"Patrick D W Kiely, Bayram Farisogullari, Stephanie Finzel, Graeme J Carroll, Geraldine McCarthy, John Stack, Simone Parisi, Graça Porto, Pascal Richette, Gyorgy Nagy, Marton Weidl, Ann Rosenthal, Pascal Guggenbuhl, Katarzyna J Banaszkiewicz, Svenja Engelhardt, Jeremy D Shearman, David Mitchell, Barbara Butzeck, Howard Don, Jane Barker, Valerie Brueton, Philip Coathup, Jacqueline Dowsett, Marie Duncan, Tracey Dunleavy, Ian Fish, Allin Hoggarth, Mark McKinnon, James Minter, Tim Osborne, Marguerite Smith, Christine Wright, Pedro M Machado","doi":"10.1016/j.ard.2026.10.3166","DOIUrl":"https://doi.org/10.1016/j.ard.2026.10.3166","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to determine the association of recognised HFE genotypes with arthropathy fulfilling European Alliance of Associations for Rheumatology (EULAR) haemochromatosis arthropathy (HA) classification criteria (CC), and the contributory role of iron loading.</p><p><strong>Methods: </strong>We analysed 373 participants from the EULAR HA inception cohorts: group 1, C282Y homozygous with significant iron overload (n = 154); group 2A, C282Y homozygous without significant iron overload (n = 27); group 2B, other HFE genotypes irrespective of iron status (n = 72); group 3 (osteoarthritis/calcium pyrophosphate arthropathy controls without iron overload (n = 120). Group 2 were selected from rheumatology patients with persistent unexplained joint pain, potential HA, and/or pre-existing genotyping. Between-group comparisons and genotype-stratified analyses were performed. In group 2, associations among ferritin, transferrin saturation, and HA-CC fulfilment were assessed using regression analyses.</p><p><strong>Results: </strong>HA-CC were fulfilled in 71.4% of group 1, 22.2% group 2A, 43.1% group 2B, and 6.7% group 3 (P < .001 all comparisons). Compared with group 3, group 2 demonstrated significantly higher prevalence of HA-CC fulfilment and 5 HA-CC features (P < .003 all items), including participants with H63D variants. Ferritin levels and transferrin saturation were not associated with HA-CC fulfilment odds ratio (OR) 1.000 per 1 µg/L increase, 95% CI: 1.000-1.001, P = .28; OR 0.98 per 1% increase, 95% CI: 0.96-1.01, P = .14, respectively).</p><p><strong>Conclusions: </strong>A substantial proportion of individuals without haemochromatosis but carrying HFE genotypes fulfil EULAR HA-CC, without an association with ferritin levels or transferrin saturation. This supports a potential iron-independent contribution of HFE variants to arthropathy. Although 'haemochromatosis arthropathy' is found in people with genetic haemochromatosis, 'HFE associated arthropathy without genetic haemochromatosis' describes metacarpophalangeal and/or ankle joint disease with any HFE genotype.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nicotinamide N-methyltransferase drives fibroblast activation and skin fibrosis in systemic sclerosis.","authors":"Anela Tosevska, Karolina von Dalwigk, Shaohua Zhu, Jiajia Pang, Lisa Gröbl, Ece Danisman, Felix Kartnig, Ana Korosec, Birgit Niederreiter, Lukas Kremp, Carl Walter Steiner, Juan Manuel Sacnun, Stephan Blüml, Thomas Köcher, Daniel Aletaha, Hans P Kiener, Leonhard X Heinz, Peter M Heil, Beate M Lichtenberger, Thomas Karonitsch","doi":"10.1016/j.ard.2026.10.3163","DOIUrl":"https://doi.org/10.1016/j.ard.2026.10.3163","url":null,"abstract":"<p><strong>Objectives: </strong>Systemic sclerosis (SSc) is characterised by persistent fibroblast activation and progressive extracellular matrix (ECM) accumulation. The mechanisms sustaining profibrotic fibroblast states remain poorly understood. Nicotinamide N-methyltransferase (NNMT), a S-adenosylmethionine (SAM)-consuming enzyme that modulates cellular methylation potential, has been implicated in fibrotic tissue remodelling. In this study, we investigated the role of NNMT in dermal fibroblast (DF) activation and fibrosis in SSc.</p><p><strong>Methods: </strong>Bulk RNA-sequencing (RNA-Seq), single-cell RNA-seq and spatial transcriptomics datasets from SSc skin were analysed. Primary human DFs were subjected to small interfering RNA (siRNA)-mediated NNMT knockdown or pharmacological NNMT inhibition followed by transcriptomic, metabolomic, epigenetic, and functional profiling. Downstream transcription factors were assessed by QuantSeq 3' RNA-Seq following activating transcription factor 4 (ATF4), SRY-box transcription factor (SOX9), and serum response factor (SRF) knockdown. Pharmacological NNMT inhibition was evaluated in bleomycin-induced dermal fibrosis.</p><p><strong>Results: </strong>NNMT was upregulated in SSc skin across independent cohorts and enriched in disease-expanded myofibroblast states. NNMT knockdown altered the SAM/S-adenosylhomocysteine ratio and histone methylation patterns, and attenuated transforming growth factor-β (TGFβ)-induced profibrotic programs associated with ECM production, collagen synthesis and tissue remodelling. Mechanistically, NNMT supported TGFβ-induced activation of an ATF4/SOX9/SRF transcriptional network that contributed to ECM gene expression and collagen secretion. Pharmacological NNMT inhibition recapitulated key effects of NNMT depletion, suppressed disease-associated SSc fibroblast programs, and attenuated experimental dermal fibrosis in vivo.</p><p><strong>Conclusions: </strong>These findings identify a TGFβ-NNMT-ATF4/SOX9/SRF regulatory network linking metabolic regulation to DF activation. Targeting NNMT may represent a therapeutic strategy to attenuate fibrosis in SSc.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis-a case series.","authors":"Elise Siegert, Elpida Phithak, Fredrik N Albach, Robert Biesen, Norman Michael Drzeniek, Maria Dzamukova, Isabell Haase, Klaus Søndergaard, Dorothea Schleser, Leonard Fiebig, Arne Sattler, Ioanna Minopoulou, Marie Chiara Rehm, Phillip Kremer, Udo Schneider, Sofia Trezzini, Anna Maria Claire Rein, Clara Marisa Mayer, Felix Doellinger, Christian Furth, Anja Staeck, Qingyu Cheng, Benedikt Sinzinger, Nadine Unterwalder, Sarah Ohrndorf, Meike Probst, Yaosi Li, Daniel Grund, Thula Walter-Rittel, Anja Fleischmann, Edgar Wiebe, Marie Luise Hütter-Krönke, Ulrich Keller, Jan Krönke, Antonia Busse, Arnd Kleyer, Ann-Christin Pecher, Jörg Henes, Anne Troldborg, Anja Erika Hauser, Ina Kötter, Martin Krusche, Gerhard Krönke, Tobias Alexander, David Simon","doi":"10.1016/j.ard.2026.05.023","DOIUrl":"10.1016/j.ard.2026.05.023","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate clinical outcomes, serologic changes, and immunologic effects induced by the bispecific B cell Maturation Antigen (BCMA)x Cluster of Differentiation (CD)3 T-cell-engaging antibody teclistamab in systemic sclerosis (SSc).</p><p><strong>Methods: </strong>Patients with severe and treatment-refractory SSc were treated with teclistamab as off-label therapy. Blood and tissue samples from skin and bone marrow were analysed with immunohistochemistry and flow cytometry, serum antibodies were quantified by enzyme-linked immunosorbent assay (ELISA). Clinical efficacy was assessed using the American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS) responses, among others.</p><p><strong>Results: </strong>Ten patients with SSc (70% female; median age 51 years [IQR: 7]) completed 1 cycle of teclistamab. Two patients with advanced SSc heart involvement died shortly after treatment initiation. B-cells and plasma cells were almost completely eliminated from bone marrow and skin, accompanied by a median reduction of 70.6% (IQR: 39%) in antitopoisomerase antibody titres, decreases in serum IgG, and vaccination titres. After a median follow-up of 3.75 months (IQR: 2.5 months), 71% and 43% of patients achieved revised ACR-CRISS 25 and 50 responses, respectively. Among patients with interstitial lung disease, radiographic and functional improvement was observed by week 12 with a median increase in forced vital capacity of 7% (IQR: 15%). Skin fibrosis similarly improved, with a median decrease in the modified Rodnan skin score of 35.9% (IQR: 17.9%), accompanied by corresponding reductions in fibroblast activation protein (FAP)-alpha-positive fibroblasts in skin biopsy specimens.</p><p><strong>Conclusions: </strong>Teclistamab induced deep tissue depletion of B-cells and plasma cells and rapid clinical and serological responses, with evidence for resolution of inflammation and potential modification of fibrotic processes. These data suggest the potential of BCMA-directed therapies to promote immune modulation and tissue remodelling.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"2194-2207"},"PeriodicalIF":24.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148275821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-defined presynovitis is associated with progression to clinical arthritis in ACPA-positive individuals at risk of rheumatoid arthritis: longitudinal insights from the Karolinska Risk-RA cohort.","authors":"Yogan Kisten, Alexandra Cîrciumaru, Marina Dehara, Caroline Grönwall, Linda Mathsson-Alm, Monika Hansson, Karin Lundberg, Cidem Gentline, Nancy Vivar Pomiano, Aase Hensvold, Katerina Chatzidionysiou, Sofia Geschwind, Per-Johan Jakobsson, Erik Af Klint, Johan Askling, Helga Westerlind, Hamed Rezaei, Lars Klareskog","doi":"10.1016/j.ard.2026.06.022","DOIUrl":"10.1016/j.ard.2026.06.022","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate whether ultrasound (US)-detected features preceding Doppler-active synovitis are associated with progression to clinical arthritis in anticitrullinated protein antibody (ACPA)-positive individuals with musculoskeletal (MSK) symptoms.</p><p><strong>Methods: </strong>In this prospective cohort study, 309 ACPA-positive individuals with MSK symptoms but without clinical arthritis and Doppler-active synovitis were included. US assessments evaluated minimal US findings, including synovial thickening, tendon sheath involvement, bursal effusions, and bone surface cortical irregularities. Longitudinal within-individual trajectories of US findings were analysed over time. Anticyclic citrullinated peptide 2 immunoglobulin G (IgG) and IgM rheumatoid factor (IgM RF) were measured at inclusion. The primary outcome was development of clinical arthritis over 3 years. Associations were analysed using Cox regression and logistic regression models.</p><p><strong>Results: </strong>During a median follow-up of 13 months (IQR 7-22), 117 of 309 participants (38%) developed clinical arthritis, of whom 97 of 117 (83%) fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism rhematoid arthritis classification criteria. Any US finding at baseline (75/309) was associated with a 3-fold increased risk of arthritis development (51/117 progressors vs 24/192 nonprogressors; hazard ratio [HR] 3.3, 95% CI 2.3-4.8). Among these, tendon sheath involvement showed the strongest association (HR 3.6, 95% CI 2.4-5.4), especially in combination with IgM RF positivity (HR 4.2, 95% CI 2.7-6.4). Longitudinal trajectories demonstrated progressive accumulation of US findings prior to arthritis onset, whereas such findings remained infrequent among nonprogressors. Tendon involvement frequently preceded synovial changes.</p><p><strong>Conclusions: </strong>Minimal US findings preceding Doppler-active synovitis, particularly tendon involvement, were strongly associated with progression to clinical arthritis in ACPA-positive individuals and support an US-identified 'presynovitis' phase of rheumatoid arthritis development and early risk stratification.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"2107-2118"},"PeriodicalIF":24.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148496938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia Ann Rheum Dis. 2025 Sep;84(9):1445-1457. doi: 10.1016/j.ard.2025.01.021. Epub 2025 May 8.","authors":"H W van Steenbergen, F Doornkamp, S Alivernini, J Backlund, C Codreanu, S B Cohen, B Combe, A P Cope, K D Deane, B R England, M Falahee, P H P de Jong, A Kleyer, D Lacaille, B Maat, K Mankia, E van Mulligen, G Nagy, L J O'Neil, L Rodamaker, I Sahbudin, D van Schaardenburg, A Sepriano, J A P da Silva, L De Smet, J A Sparks, E W Steyerberg, P Studenic, E Wethington, R L Landewé, K Raza, A H M van der Helm-van Mil","doi":"10.1016/j.ard.2026.07.009","DOIUrl":"10.1016/j.ard.2026.07.009","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"e136"},"PeriodicalIF":24.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year.","authors":"Andreu Fernández-Codina, Susan J Bartlett, Carter Thorne, Glen Hazlewood, Marie-France Valois, Hughes Allard-Chamard, Louis Bessette, Carol A Hitchon, Bindee Kuriya, Vivian P Bykerk, Janet E Pope","doi":"10.1016/j.ard.2026.08.001","DOIUrl":"10.1016/j.ard.2026.08.001","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to determine whether the route of glucocorticoid (GC) administration in patients with early rheumatoid arthritis (ERA) is associated with the odds of persistent GC use or escalation to advanced therapies at 12 months.</p><p><strong>Methods: </strong>Adults with newly diagnosed ERA (symptoms duration <1 year) enrolled in the Canadian Early Arthritis Cohort between 2007 and 2023 were included. Those with GC use 90 days prior to baseline, on advanced therapy by 3 months, or with <12 months of follow-up were excluded. Patients were stratified by GC use and route in the first 3 months and compared using analysis of variance or Wilcoxon tests. Adjusted multivariable logistic regression was used to calculate the odds ratios (OR).</p><p><strong>Results: </strong>Among 2222 patients, median (SD) age was 55 (15) years, disease duration 5.5 (3.0) months, and the Clinical Disease Activity Index was 26 (14). During the first 3 months, 1661 patients (75%) received no GC, 421 (19%) oral, 121 (5%) parenteral (intra-articular and/or intramuscular), and 19 (1%) both oral and parenteral. Advanced therapies and GC use, respectively, at 12 months were 7% and 8% (no GC); 14% and 47% (oral); 14% and 26% (parenteral); 16% and 63% (both). The OR for GC use at 1 year was 9.8 (oral) and 4.1 (parenteral), compared with no GC (1.0).</p><p><strong>Conclusions: </strong>Patients receiving parenteral GC were half as likely to remain on GC at 12 months compared with those on oral GC. Rates of advanced therapy use were similar between groups. Parenteral GC administration may facilitate earlier discontinuation of steroids.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"2129-2135"},"PeriodicalIF":24.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence on 'Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)' by Imai et al.","authors":"Preeti Lamba, Dharmendra Sharma","doi":"10.1016/j.ard.2026.04.012","DOIUrl":"https://doi.org/10.1016/j.ard.2026.04.012","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":"85 11","pages":"e131-e132"},"PeriodicalIF":24.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149293964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}